221 related articles for article (PubMed ID: 33369672)
1. Comparative risks of cardiovascular disease events among SLE patients receiving immunosuppressive medications.
Choi MY; Li D; Feldman CH; Yoshida K; Guan H; Kim SC; Everett BM; Costenbader KH
Rheumatology (Oxford); 2021 Aug; 60(8):3789-3798. PubMed ID: 33369672
[TBL] [Abstract][Full Text] [Related]
2. Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications.
Feldman CH; Marty FM; Winkelmayer WC; Guan H; Franklin JM; Solomon DH; Costenbader KH; Kim SC
Arthritis Rheumatol; 2017 Feb; 69(2):387-397. PubMed ID: 27589220
[TBL] [Abstract][Full Text] [Related]
3. Azathioprine and Mycophenolate Mofetil Adherence Patterns and Predictors Among Medicaid Beneficiaries With Systemic Lupus Erythematosus.
Feldman CH; Collins J; Zhang Z; Xu C; Subramanian SV; Kawachi I; Solomon DH; Costenbader KH
Arthritis Care Res (Hoboken); 2019 Nov; 71(11):1419-1424. PubMed ID: 30354025
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil.
Prasad N; Kurian J; Agarwal V; Bhadauria D; Behera M; Yacha M; Kushwaha R; Agrawal V; Jain M; Gupta A
Lupus; 2020 Jul; 29(8):845-853. PubMed ID: 32437258
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of tacrolimus, mycophenolate mofetil, azathioprine, and cyclophosphamide as maintenance therapy for lupus nephritis : A Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Z Rheumatol; 2017 Dec; 76(10):904-912. PubMed ID: 27638015
[TBL] [Abstract][Full Text] [Related]
6. The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritis.
Koo HS; Kim YC; Lee SW; Kim DK; Oh KH; Joo KW; Kim YS; Ahn C; Han JS; Kim S; Chin HJ
Lupus; 2011 Nov; 20(13):1442-9. PubMed ID: 21951944
[TBL] [Abstract][Full Text] [Related]
7. Association of mycophenolate and azathioprine use with cognitive function in systemic lupus.
Dobrowolski C; McGinley J; Fazzari M; Su J; Bingham KS; Anderson N; Ruttan L; Beaton DE; Wither JE; Tartaglia MC; Kakvan M; Bonilla D; Choi MY; Fritzler MJ; Diaz Martinez JP; Katz P; Green R; Putterman C; Touma Z
Rheumatology (Oxford); 2023 May; 62(5):1860-1869. PubMed ID: 36135792
[TBL] [Abstract][Full Text] [Related]
8. Changes in immune cell frequencies after cyclophosphamide or mycophenolate mofetil treatments in patients with systemic lupus erythematosus.
Zhao L; Jiang Z; Jiang Y; Ma N; Wang K; Zhang Y
Clin Rheumatol; 2012 Jun; 31(6):951-9. PubMed ID: 22349930
[TBL] [Abstract][Full Text] [Related]
9. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.
Moroni G; Raffiotta F; Trezzi B; Giglio E; Mezzina N; Del Papa N; Meroni P; Messa P; Sinico AR
Rheumatology (Oxford); 2014 Sep; 53(9):1570-7. PubMed ID: 24505125
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials.
Zhu B; Chen N; Lin Y; Ren H; Zhang W; Wang W; Pan X; Yu H
Nephrol Dial Transplant; 2007 Jul; 22(7):1933-42. PubMed ID: 17405792
[TBL] [Abstract][Full Text] [Related]
11. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide.
Contreras G; Tozman E; Nahar N; Metz D
Lupus; 2005; 14 Suppl 1():s33-8. PubMed ID: 15803929
[TBL] [Abstract][Full Text] [Related]
12. Initial disease severity, cardiovascular events and all-cause mortality among patients with systemic lupus erythematosus.
Li D; Yoshida K; Feldman CH; Speyer C; Barbhaiya M; Guan H; Solomon DH; Everett BM; Costenbader KH
Rheumatology (Oxford); 2020 Mar; 59(3):495-504. PubMed ID: 31321417
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolic acid counteracts B cell proliferation and plasmablast formation in patients with systemic lupus erythematosus.
Eickenberg S; Mickholz E; Jung E; Nofer JR; Pavenstadt HJ; Jacobi AM
Arthritis Res Ther; 2012; 14(3):R110. PubMed ID: 22571761
[TBL] [Abstract][Full Text] [Related]
14. Two cases of refractory thrombocytopenia in systemic lupus erythematosus that responded to intravenous low-dose cyclophosphamide.
Park HJ; Kang MI; Kang Y; Chung SJ; Lee SW; Park YB; Lee SK
J Korean Med Sci; 2013 Mar; 28(3):472-5. PubMed ID: 23487584
[TBL] [Abstract][Full Text] [Related]
15. Race/Ethnicity and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus.
Barbhaiya M; Feldman CH; Guan H; Gómez-Puerta JA; Fischer MA; Solomon DH; Everett B; Costenbader KH
Arthritis Rheumatol; 2017 Sep; 69(9):1823-1831. PubMed ID: 28598016
[TBL] [Abstract][Full Text] [Related]
16. The use of low-dose cyclophosphamide followed by AZA/MMF treatment in childhood lupus nephritis.
Baskin E; Ozen S; Cakar N; Bayrakci US; Demirkaya E; Bakkaloglu A
Pediatr Nephrol; 2010 Jan; 25(1):111-7. PubMed ID: 19727839
[TBL] [Abstract][Full Text] [Related]
17. Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis.
Lee YH; Woo JH; Choi SJ; Ji JD; Song GG
Lupus; 2010 May; 19(6):703-10. PubMed ID: 20064907
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus.
Fassbinder T; Saunders U; Mickholz E; Jung E; Becker H; Schlüter B; Jacobi AM
Arthritis Res Ther; 2015 Apr; 17(1):92. PubMed ID: 25890338
[TBL] [Abstract][Full Text] [Related]
19. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.
Houssiau FA; D'Cruz D; Sangle S; Remy P; Vasconcelos C; Petrovic R; Fiehn C; de Ramon Garrido E; Gilboe IM; Tektonidou M; Blockmans D; Ravelingien I; le Guern V; Depresseux G; Guillevin L; Cervera R;
Ann Rheum Dis; 2010 Dec; 69(12):2083-9. PubMed ID: 20833738
[TBL] [Abstract][Full Text] [Related]
20. Analysis of trends and causes of death in SLE patients over a 40-years period in a cohort of patients in the United Kingdom.
Lorenzo-Vizcaya A; Isenberg D
Lupus; 2021 Apr; 30(5):702-706. PubMed ID: 33472522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
